(1-benzyl-5-(4-(trifluoromethoxy)phenyl)-1H-indol-3-yl)(oxo)acetic acid,
PAI 039,
PAI-039,
PAI039 cpd,
tiplaxtinin,
Tiplaxtinin,
393105-53-8,
Tiplasinin,
PAI-039,
PAI 039,
Tiplaxtinin(PAI-039),
UNII-L396QIB983,
Tiplaxtinin (PAI-039),
1H-Indole-3-aceticacid, a-oxo-1-(phenylmethyl)-5-[4-(trifluoromethoxy)phenyl]-,
CHEMBL325441,
L396QIB983,
2-(1-benzyl-5-(4-(trifluoromethoxy)phenyl)-1H-indol-3-yl)-2-oxoacetic acid,
2-[1-benzyl-5-[4-(trifluoromethoxy)phenyl]indol-3-yl]-2-oxoacetic acid,
2-{1-benzyl-5-[4-(trifluoromethoxy)phenyl]-1H-indol-3-yl}-2-oxoacetic acid,
Tiplasinin [USAN:INN],
Tiplasinin (USAN),
tiplaxtinin-pai-039,
AC1O52EL,
MLS006010332,
SCHEMBL3052065,
CTK4I1261,
Tiplaxtinin, >=98% (HPLC),
AOB2258,
DTXSID30192548,
EX-A114,
ODXQFEWQSHNQNI-UHFFFAOYSA-N,
BCPP000043,
BCP02216,
ZINC3938676,
BDBM50149275,
MFCD09475615,
s7922,
(1-benzyl-5-(4-(trifluoromethoxy)phenyl)-1H-indol-3-yl)oxoacetic acid,
[1-Benzyl-5-(4-trifluoromethoxy-phe,
AKOS026750318,
CS-3928,
nyl)-1H-indol-3-yl]-oxo-acetic acid,
VA11996,
NCGC00263142-01,
NCGC00263142-04,
4CA-1254,
AK341044,
BC213241,
HY-15253,
SMR004701395,
LS-191839,
B5906,
FT-0700303,
J3.621.696D,
A14190,
D06160,
J-690292,
3,3'-((5-Fluoropyrimidine-2,4-diyl)bis(azanediyl))diphenol,
[{1-benzyl-5-[4-(trifluoromethoxy)phenyl]-1H-indol-3-yl}(oxo)acetic acid,
[1-Benzyl-5-(4-trifluoromethoxy-phenyl)-1H-indol-3-yl]-oxo-acetic acid,
{1-Benzyl-5-[4-(trifluoromethoxy)phenyl]-1H-indol-3-yl}(oxo)acetic Acid,
2-[1-Benzyl-5-[4-(trifluoromethoxy)phenyl]indol-3-yl]-2-oxo-acetic aci d,
2-{1-benzyl-5-[4-(trifluoromethoxy)phenyl]-1H-indol -3-yl}-2-oxoacetic acid,
Tiplasinin < USAN,
Tiplasinin [USAN],
Prop INN >,
Tiplaxtinin (formerly),
PAI039 cpd,
D02QBJ,
CID6450819,
C488103,
(1-benzyl-5-(4-(trifluoromethoxy)phenyl)-1H-indol-3-yl)(oxo)acetic acid,
?-Oxo-1-(phenylmethyl)-5-[4-(trifluoromethoxy)phenyl]-1H-indole-3-acetic acid,
2-[1-Benzyl-5-[4-(trifluoromethoxy)phenyl]-1H-indol-3-yl]-2-oxoacetic acid,